ClinicalTrials.gg
Not yet recruitingNCT05169021FAITHUpdated Dec 23, 2021

Folic Acid and Intensive Antihypertensive Therapy for Hypertension With CSVD

A Phase 4 interventional study of Amlodipine folic acid 5.8mg+intensive antihypertensive therapy and Amlodipine folic acid 5.8mg+standard antihypertensive therapy in Cerebral Small Vessel Diseases and Stroke, sponsored by Beijing Tiantan Hospital. Not yet recruiting at 1 site in China. Open to participants aged 35 Years to 75 Years. Per ClinicalTrials.gov, last updated 2021-12-23.

Sponsored by Beijing Tiantan Hospital · Phase 4, Interventional, and Prevention

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2024, 1 year 10 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
15,000
Allocation
Randomized
Ages
35 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies in Cerebral Small Vessel Diseases by Beijing Tiantan Hospital — 6 open to participants now, 7 under way, 1 of them phase 3. Cerebral Small Vessel Diseases · Beijing Tiantan Hospital.

Started
2021
the only one that year
Phase 4
3 of 10
1 open now
Registered
1st of 10
by date

Among the 10 studies in Cerebral Small Vessel Diseases by Beijing Tiantan Hospital, this one is the only one that started in 2021, is one of 3 in phase 4, and was the 1st registered.

Cerebral Small Vessel Diseases

128 studies on the registry are indexed under Cerebral Small Vessel Diseases; 71 are open to participants now.

Browse Cerebral Small Vessel Diseases studies →

Open to participants now

6 of the 10 studies in Cerebral Small Vessel Diseases by Beijing Tiantan Hospital are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 46 Cerebral Small Vessel Diseases studies recruiting now, 26 (57%) set no upper age limit and 5 (11%) stop at 75 or younger; 2 take children under 18; 11 take healthy volunteers.

This study: 35 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Cerebral Small Vessel Diseases by Beijing Tiantan Hospital, or all of them as a file.
02

Study summary

The primary objectives of this trial are:

  1. Efficacy evaluation of amlodipine folic acid tablets:

    To assess the effects of amlodipine folic acid tablets 5.8 mg (5 mg amlodipine + 0.8 mg folic acid)versus amlodipine tablets 5 mg in preventing all-cause stroke in cerebral small vascular disease (CSVD) patients with hypertension and elevated homocysteine (Hcy) level.

  2. Intensive Antihypertensive Therapy:

To assess the effect of intensive antihypertensive therapy (SBP\<130 mmHg) versus standard antihypertensive therapy (SBP 130-\<140 mmHg) in reducing risk of combined cardio-cerebrovascular events in CSVD patients with hypertension and elevated Hcy level, using two basic anti-hypertensive drugs, amlodipine tablets 5 mg or amlodipine folic acid tablets 5.8 mg.

Read the detailed description

Hypertension is highly prevalent risk factor for stroke, particularly for stroke associated with CSVD. Blood pressure (BP) lowering has been considered an important measure for preventing stroke and progression of CSVD. Moreover, uncertainty remains regarding the efficacy of folic acid therapy for secondary prevention of stroke because of limited and inconsistent data. We propose to conduct a randomized, double-blind, placebo-controlled, multicenter, 2×2 factorial designed clinical trial to test the primary hypothesis that 1) whether amlodipine folic acid is more effective than amlodipine in reducing the risk of all-cause stroke (including fatal and non-fatal stroke) over a follow-up period among patients with CSVD. 2) whether an intensive treatment strategy (a systolic BP target of \<130mmHg) is more effective than a standard treatment strategy (a systolic BP target of 130-140mmHg) in reducing the risk of combined cardio-cerebrovascular events.

Both Intention-to-treat Analysis (ITT) and Per-protocol set (PPS) were used for analysis.

We will use Kaplan-Meier estimates of the cumulative risk of stroke (ischemic or hemorrhagic) event and combined cardio-cerebrovascular events during follow-up period, with hazards ratios and 95% CI calculated using Cox proportional hazards methods and the log-rank test to evaluate the treatment effect. All statistics will be 2-sided with P\<0.05 considered significant, accounting for interim analyses.

All patients who received study drugs and with at least one safety follow-up record will be included in the safety population. The data for safety evaluation included adverse reactions observed during the trial and changes in laboratory data before and after treatment.

03

Conditions studied

  • Cerebral Small Vessel Diseases
  • Stroke

Keywords

  • Cerebral Small Vessel Diseases
  • Stroke recurrence
  • Hypertension
  • Homocysteine
  • Folic acid
04

Who can participate

Ages eligible
35 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age 35-75 years;
  2. Meets any of the following criteria:
  1. Lacunar infarction occurring within the period of seven days up to one year post-infarction, diagnosed by head MRI/CT (meeting modified Fisher criteria*); 2)Head MRI indicating white matter hyperintensity, 4≥Fazekas score*≥2; 3)Head MRI indicating white matter hyperintensity, Fazekas=1, combined with old subcortical vascular lacunar infarction;
  • For modified Fisher criteria and Fazekas score, see FAITH main study appendix 1 and appendix 6).

    1. Medical recorded history of hypertension. Systolic blood pressure SBP: 130-180 mm Hg on 0 or 1 medication SBP: 130-170 mm Hg on up to 2 medications SBP: 130-160 mm Hg on up to 3 medications. 4. mRS score ≤2; 5. Serum Hcy ≥10 µmol/L or MTHFR 677 TT genotype; 6. Signed form.

Exclusion criteria

Exclusion Criteria:

  1. Patients with secondary hypertension;
  2. Symptomatic intracranial and extracranial artery stenosis (stenosis ≥50%), or asymptomatic intracranial and extracranial artery stenosis (stenosis≥70%);
  3. Patients who have undergone revascularization of the heart, brain, or kidney, or other aortic stenting procedures;
  4. Any symptoms of orthostatic hypotension when measuring standing blood pressure, or if standing SBP \<110mmHg;
  5. Bilateral renal artery stenosis;
  6. Patients who have previously taken candesartan or other angiotensin receptor antagonist (ARB) type medication, indapamide or other similar diuretic type medication, or any medication or health product containing folic acid, and reported adverse reactions;
  7. Patients who have indicators for specific antihypertensive medications (e.g. β-blockers after acute myocardial infarction, RAS blockers for prevention of cardiovascular disease, α-blockers for treatment of benign prostate hyperplasia);
  8. Within the last three months, regular usage of vitamin supplements containing folic acid, B6, or B12, or usage of folic acid antagonists (e.g. methotrexate);
  9. Patients undergoing dialysis or with stage 4-5 chronic kidney disease, or estimated (eGFR) \<30 mL/min/1.73m²;
  10. History of epilepsy or currently using anti-epileptic medication;
  11. Pregnant and lactating women, or women planning to become pregnant;
  12. less than four years;
  13. Within the last month, participation in another clinical trial;
  14. Any patient determined by the researchers to be unsuitable for the present study.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
15,000 participants (estimated)

Study arms

  • Active comparator
    Amlodipine folic acid 5.8mg+intensive antihypertensive therapy

    This group will receive intensive antihypertensive therapy (systolic blood pressure(SBP) \<130 mmHg); with amlodipine folic acid 5.8mg.

    Drug: Amlodipine folic acid 5.8mg+intensive antihypertensive therapy

  • Active comparator
    Amlodipine folic acid 5.8mg+standard antihypertensive therapy

    This group will receive standard antihypertensive therapy (SBP: 130-140 mmHg); with amlodipine folic acid 5.8mg.

    Drug: Amlodipine folic acid 5.8mg+standard antihypertensive therapy

  • Active comparator
    Amlodipine+intensive antihypertensive therapy

    This group will receive intensive antihypertensive therapy (systolic blood pressure(SBP) \<130 mmHg); with amlodipine 5.0mg.

    Drug: Amlodipine+intensive antihypertensive therapy

  • Placebo comparator
    Amlodipine+standard antihypertensive therapy

    This group will receive standard antihypertensive therapy (SBP: 130-140 mmHg); with amlodipine 5.0mg.

    Drug: Amlodipine+standard antihypertensive therapy

Interventions

  • DrugAmlodipine folic acid 5.8mg+intensive antihypertensive therapy

    Amlodipine folic acid tablet 5.8mg, taken daily, in the morning after waking. To achieve target blood pressure(SBP\<130mmHg), this study will provide, if needed, concurrent antihypertensive medications. Patients will be asked to discontinue all prior concurrent medications. Recommended treatment options are described below: 1. Add candesartan 4mg; 2. Add indapamide 2.5mg; 3. Increase dose of candesartan to 8mg; 4. Increase dose of amlodipine to 7.5mg-10mg.

  • DrugAmlodipine folic acid 5.8mg+standard antihypertensive therapy

    Amlodipine folic acid tablet 5.8mg, taken daily, in the morning after waking. To achieve target blood pressure (SBP:130-140mmHg), this study will provide, if needed, concurrent antihypertensive medications. Patients will be asked to discontinue all prior concurrent medications. Recommended treatment options are described below: 1. Add candesartan 4mg; 2. Add indapamide 2.5mg; 3. Increase dose of candesartan to 8mg; 4. Increase dose of amlodipine to 7.5mg-10mg.

  • DrugAmlodipine+intensive antihypertensive therapy

    Amlodipine tablet 5.8mg, taken daily, in the morning after waking. To achieve target blood pressure (SBP: 130-140 mmHg), this study will provide, if needed, concurrent antihypertensive medications. Patients will be asked to discontinue all prior concurrent medications. Recommended treatment options are described below: 1. Add candesartan 4mg; 2. Add indapamide 2.5mg; 3. Increase dose of candesartan to 8mg; 4. Increase dose of amlodipine to 7.5mg-10mg.

  • DrugAmlodipine+standard antihypertensive therapy

    Amlodipine tablet 5.8mg, taken daily, in the morning after waking. To achieve target blood pressure (SBP: 130-140 mmHg), this study will provide, if needed, concurrent antihypertensive medications. Patients will be asked to discontinue all prior concurrent medications. Recommended treatment options are described below: 1. Add candesartan 4mg; 2. Add indapamide 2.5mg; 3. Increase dose of candesartan to 8mg; 4. Increase dose of amlodipine to 7.5mg-10mg.

    Also known as: Standard antihypertensive therapy

06

What researchers measure

Primary outcomes

  1. All-cause stroke (including fatal and non-fatal stroke)

    This aims to assess the effects of amlodipine folic acid tablets 5.8 mg (5 mg amlodipine + 0.8 mg folic acid)versus amlodipine tablets 5 mg in preventing stroke occurrence in cerebral small vascular disease (CSVD) patients with hypertension and elevated homocysteine (Hcy) level

    Time frame: 4 year after randomization

  2. Combined cardio-cerebrovascular events

    This aims to assess the effect of intensive antihypertensive therapy (SBP\<130 mmHg) versus standard antihypertensive therapy (SBP 130-\<140 mmHg) in reducing risk of combined cardio-cerebrovascular events in CSVD patients with hypertension and elevated Hcy level.

    Time frame: 4 year after randomization

Secondary outcomes

  1. Combined cardio-cerebrovascular events

    Secondary outcome for assessing the effects of amlodipine folic acid tablets 5.8 mg (5 mg amlodipine + 0.8 mg folic acid)versus amlodipine tablets 5 mg in preventing combined cardio-cerebrovascular events in cerebral small vascular disease (CSVD) patients with hypertension and elevated homocysteine (Hcy) level.

    Time frame: 4 year after randomization

  2. All-cause stroke (including fatal and non-fatal stroke)

    Secondary outcome for assessing the effect of intensive antihypertensive therapy (SBP\<130 mmHg) versus standard antihypertensive therapy (SBP 130-\<140 mmHg) in reducing risk of stroke occurrence in CSVD patients with hypertension and elevated Hcy level.

    Time frame: 4 year after randomization

  3. Ischemic stroke

    Percentage of patients within follow-up period new ischemic stroke events.

    Time frame: 4 year after randomization

  4. Hemorrhagic stroke

    Percentage of patients within follow-up period new hemorrhagic stroke events.

    Time frame: 4 year after randomization

  5. Myocardial infarction

    Percentage of patients within follow-up period new myocardial infarction events.

    Time frame: 4 year after randomization

  6. Hospitalization from heart failure

    Hospitalization, or an emergency department visit requiring treatment with infusion therapy, for a clinical syndrome that presents with multiple signs and symptoms consistent with cardiac decompensation/ inadequate cardiac pump function within follow-up period.

    Time frame: 4 year after randomization

  7. Cardio-cerebrovascular death

    Cardio-cerebrovascular death includes death caused by acute myocardial infarction (MI), sudden cardiac death, death caused by heart failure (HF), death caused by stroke, death caused by cardiovascular surgery, death caused by cardiovascular hemorrhage and other cardiovascular causes.

    Time frame: 4 year after randomization

  8. All-cause death

    This is death due to various causes, including cardiovascular and non-vascular deaths and deaths from unknown causes.

    Time frame: 4 year after randomization

Other outcomes

  1. Malignant tumors occurence

    To assess the effects of amlodipine folic acid tablets 5.8 mg (5 mg amlodipine + 0.8 mg folic acid)versus amlodipine tablets 5 mg in preventing malignant tumors occurrence in cerebral small vascular disease (CSVD) patients with hypertension and elevated homocysteine (Hcy) level.

    Time frame: 4 year after randomization

  2. Changes in total image load score of CSVD

    Changes in total image load score of CSVD

    Time frame: 4 year after randomization

  3. Changes in WMLs and brain volume

    Changes in WMLs and brain volume

    Time frame: 4 year after randomization

  4. Changes in score of each single item of the grading of CSVD image load

    Changes in score of each single item of the grading of CSVD image load

    Time frame: 4 year after randomization

  5. Changes in autonomic nervous system function and cerebral hemodynamics

    Changes in autonomic nervous system function and cerebral hemodynamics

    Time frame: 4 year after randomization

  6. Changes in MoCA score

    Changes in MoCA score

    Time frame: 4 year after randomization

07

Study locations

1 site
08

References and documents

Publications

  • Huo Y, Li J, Qin X, Huang Y, Wang X, Gottesman RF, Tang G, Wang B, Chen D, He M, Fu J, Cai Y, Shi X, Zhang Y, Cui Y, Sun N, Li X, Cheng X, Wang J, Yang X, Yang T, Xiao C, Zhao G, Dong Q, Zhu D, Wang X, Ge J, Zhao L, Hu D, Liu L, Hou FF; CSPPT Investigators. Efficacy of folic acid therapy in primary prevention of stroke among adults with hypertension in China: the CSPPT randomized clinical trial. JAMA. 2015 Apr 7;313(13):1325-35. doi: 10.1001/jama.2015.2274. PubMed 25771069 ↗
  • Toole JF, Malinow MR, Chambless LE, Spence JD, Pettigrew LC, Howard VJ, Sides EG, Wang CH, Stampfer M. Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial. JAMA. 2004 Feb 4;291(5):565-75. doi: 10.1001/jama.291.5.565. PubMed 14762035 ↗
  • VITATOPS Trial Study Group. B vitamins in patients with recent transient ischaemic attack or stroke in the VITAmins TO Prevent Stroke (VITATOPS) trial: a randomised, double-blind, parallel, placebo-controlled trial. Lancet Neurol. 2010 Sep;9(9):855-65. doi: 10.1016/S1474-4422(10)70187-3. Epub 2010 Aug 3. PubMed 20688574 ↗
  • SPS3 Study Group; Benavente OR, Coffey CS, Conwit R, Hart RG, McClure LA, Pearce LA, Pergola PE, Szychowski JM. Blood-pressure targets in patients with recent lacunar stroke: the SPS3 randomised trial. Lancet. 2013 Aug 10;382(9891):507-15. doi: 10.1016/S0140-6736(13)60852-1. Epub 2013 May 29. Erratum In: Lancet. 2013 Aug 10;382(9891):506. Coffey, C S [aded]. PubMed 23726159 ↗
  • Croall ID, Tozer DJ, Moynihan B, Khan U, O'Brien JT, Morris RG, Cambridge VC, Barrick TR, Blamire AM, Ford GA, Markus HS; PRESERVE Study Team. Effect of Standard vs Intensive Blood Pressure Control on Cerebral Blood Flow in Small Vessel Disease: The PRESERVE Randomized Clinical Trial. JAMA Neurol. 2018 Jun 1;75(6):720-727. doi: 10.1001/jamaneurol.2017.5153. PubMed 29507944 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Dec 2021; primary completion for Dec 2024, 36 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 10, 2021
First posted
Dec 23, 2021
StartEst.
Dec 31, 2021
Primary completionEst.
Dec 31, 2024
CompletionEst.
Dec 31, 2028
Last update
Dec 23, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 23, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05169021
Responsible party
Yongjun Wang (President of Beijing Tiantan Hospital, Capital Medical University, Beijing Tiantan Hospital) — Principal investigator
First posted
Dec 23, 2021
Start date
Dec 31, 2021 (estimated)
Primary completion
Dec 31, 2024 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Dec 23, 2021

Study contacts

Jinglin Mo
Contact
mojinglin_dmu@163.com
+86 18801125231
Anxin Wang
Contact
anxin0907@163.com
0086-010-59978350
Yongjun Wang
principal investigator · Beijing Tiantan Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Dec 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion